Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-21
2010-02-09
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S364000
Reexamination Certificate
active
07659275
ABSTRACT:
In its many embodiments, the present invention provides a novel class of compounds of structural formula IA or IB where R1-R8are as disclosed hereinas inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or pharmaceutical compositions. The invention also relates to the use of a combination of a compound of this invention and one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus (HIV). The invention further relates to the use of a compound of this invention, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.
REFERENCES:
patent: 6387930 (2002-05-01), Baroudy et al.
patent: 6391865 (2002-05-01), Baroudy et al.
patent: 6602885 (2003-08-01), Baroudy et al.
patent: 6689765 (2004-02-01), Baroudy et al.
patent: 6720325 (2004-04-01), Miller
patent: 2007/0213346 (2007-09-01), Janssens et al.
patent: WO 00/66558 (2000-11-01), None
patent: WO 2004/056770 (2004-07-01), None
Gray, et al., Uncoupling Coreptor Usage of Human Immunodeficiency Virus Type 1 (HIV-1) from Macrophage Tropism Reveals Biological Properties of CCR5-restricted HIV-1 Isolates from Patients with Acquired Immunodeficiency Syndrome, Virology 337, 384-398 (2005).
West, Anthony R., Solid State Chemistry and Its Applications, Wiley, New York, 1988, 358.
International Search Report for International Application No. PCT/US2006/006333, mailed Jun. 22, 2006—4pgs.
Antonio Mastrolorenzo, et. al., Small molecule antagonists of chemokine receptors as emerging anti-HIV agents, Expert Opin. Ther. Patents, 2001, 1245-1252, 11(8).
David Chantry, HIV entry and fusion inhibitors, Expert Opin. Emerg. Drugs, 2004, 1-7, 9(1).
Christian Watson, et. al., The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor, Molecular Pharmacology, 2005, 1268-1282, 67.
Chan Tze-Ming
Feng Wenqing
Kox Kathleen
McCombie Stuart W.
Miller Michael W.
Banerjee Krishna G.
Leeser Erich A
Schering Corporation
Wilson James O
LandOfFree
Piperidinyl piperazine derivatives useful as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidinyl piperazine derivatives useful as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidinyl piperazine derivatives useful as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4215454